针对ACE2受体的吸入纳米乳液可以抑制SARS-CoV-2并减轻炎症反应
Hairui Wang1, Shuang Luo1, Mingxin Xie1
1Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041, P. R. China.
Advanced materials (Deerfield Beach, Fla.)
|January 4, 2024
概括
一种新型纳米乳液药物递送系统准了 ангиотензин转化酶2 (ACE2) 受体,以对抗冠状病毒. 这种吸入疗法抑制病毒的进入和复制,为呼吸系统疾病提供了一种新的策略.
科学领域:
- 病毒学 病毒学
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 冠状病毒对人类健康构成重大威胁,有两种主要类型利用 ангиотензин转化酶2 (ACE2) 受体进入细胞.
- 准ACE2受体结合接口为冠状病毒预防和治疗提供了一个有希望的策略.
- 药物向输送系统可以提高吸入药物的有效性和安全性.
研究的目的:
- 开发一种创新的纳米乳液 (NE) 药物输送系统用于吸入治疗,该系统针对ACE2受体.
- 评估该系统在抑制野生型和突变型冠状病毒方面的有效性.
- 评估通过该系统输送的吸入性抗炎药物对急性肺损伤的治疗潜力.
主要方法:
- 设计一种新的纳米乳液药物递送系统 (NE-AYQ),用于吸入,准ACE2受体.
- 用于抑制细胞培养中的病毒感染,给予含有remdesivir的纳米乳液 (RDSV-NE-AYQ).
- 评估该系统的双重作用:阻断细胞表面结合和抑制细胞内复制.
- 在急性肺损伤的小鼠模型中测试一种含抗炎药物纳米乳液 (TPCA-1-NE-AYQ).
主要成果:
- RDSV-NE-AYQ有效地抑制了野生型和突变型冠状病毒的感染.
- 该纳米乳液表现出双重抑制作用,阻断病毒的进入和细胞内复制.
- 在急性肺损伤的小鼠模型中,吸入TPCA-1-NE-AYQ显著减轻了肺组织损伤.
结论:
- 开发的ACE2向纳米乳液药物输送系统为冠状病毒治疗提供了一种新的方法.
- 这一策略提供了一种双重的作用机制,针对病毒的进入和复制.
- 该系统显示了吸入治疗呼吸系统疾病和未来健康紧急情况的快速发展的潜力.
更多相关视频
05:46A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
4.9K
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.7K
相关概念视频
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
257
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
257
01:19Antiasthma Drugs: Leukotriene Modifiers
306
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
306
01:17Drugs Used in Lower Respiratory Disorders: Overview
445
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
445
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
301
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
301
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
267
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
267
01:30Adrenergic Agonists: Direct-Acting Agents
1.5K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.5K